ATLANTA, GA — November 4, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX) will release its financial results for the quarter ending September 30, 2025, after U.S. markets close on Thursday, November 13, 2025.
Following the release, management will host a live conference call and audio webcast at 4:30 p.m. ET to review results and provide a business update. Participants can register in advance here to access the live conference call. The live audio webcast will be available on the Company’s Investor Relations website.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. GeoVax is also developing a vaccine targeting Mpox and smallpox and anticipates progressing directly to a Phase 3 clinical evaluation. GeoVax has a strong IP portfolio in support of its technologies and product candidates.
Company Contact:
info@geovax.com
678-384-7220
Media Contact:
Jessica Starman
media@geovax.com
Source: GeoVax Labs, Inc.
